With the Breast Cancer Working Group already announced, the pace of collaboration is accelerating to launch QUILT trials across all tumor types, guided by NantHealth's GPS Cancer test
Physicians and researchers from multiple leading institutions join to collaborate on the development of combination immunotherapy clinical trial protocols
CULVER CITY, Calif. – June 8, 2016 - Cancer Breakthroughs 2020, the world’s most comprehensive cancer collaborative initiative, today announced the formation of the Head and Neck Working Group. The team consists of scientists, physicians, and oncology professors from across the nation who have come together to focus their collective wisdom and expertise to identify and develop the most effective cancer-directed immunotherapy treatments for Head and Neck cancers.
Experts within the group will collaborate to develop clinical trial protocols, carefully studying elements such as standard of care, GPS Cancer test factors, patient selection, and appropriate combination immunotherapy approaches. GPS Cancer, offered by NantHealth, is a unique, comprehensive test integrating quantitative proteomics, and whole genome (DNA) and transcriptome (RNA) sequencing of tumor and normal germline samples to provide oncologists with a comprehensive molecular profile of a patient’s cancer to inform personalized treatment strategies and identify therapies that may have clinical benefit for the patient, including Quantitative Integrative Lifetime Trials (QUILT). GPS Cancer is performed in the CLIA-certified, CAP-accredited laboratories of NantOmics.
Key benefits of the Working Group branches of study include:
· Physicians and professionals bring their expertise and combined years of knowledge and understanding from within a specific disease study to the collective;
· Integrated research;
· Real-time communication of current data;
· Access to the most cutting edge technology available in immunotherapy research to date; and,
· A keen familiarity with the special needs of patients with specific cancers.
“By bringing together thought leaders and visionaries in the Head and Neck cancer arena, we’re continuing to support and execute against our mission of winning the war against cancer,” explained Patrick Soon-Shiong, MD, founder and CEO of NantWorks and leader of the Cancer Breakthroughs 2020 network. “Leveraging the clinical expertise of these members of the Working Group will continue to expand our network of knowledge base in immunotherapy as the next generation of standard of care in cancer patients.”
The Head and Neck Working Group will be co-chaired by John Lee, MD, Associate Professor at Sanford Health and Howard Krein, MD, PhD, Senior Director of Health Policy and Innovation at the Sidney Kimmel Cancer Center (SKCC), the Co-Director of Herbert Kean Center for Facial Aesthetics at Thomas Jefferson University and the Chief Medical Officer at StartUp Health. The two will spearhead the team’s efforts with regular meetings and development of protocols.
“By using the latest technology, we are striving to improve prevention, early detection and treatment of these tumors. Novel strategies such as vaccines and immunotherapies may decrease the incidence of these tumors and allow for new less harmful treatment modalities to help cure those already effected,” said Howard Krein, MD, PhD.
“Head and neck cancers offer an opportunity to utilize Immune Oncology treatments to improve cure rates in a cancer type. The early data shows they are responsive to immune-based approaches,” said Dr. John Lee. “The Breakthroughs protocols will offer the best ability to diagnose these tumors using the whole genome sequencing and quantitative RNA/proteomic analysis. In addition, the multiple combinations of cellular therapy, viral therapy and checkpoints.”
About Cancer Breakthroughs 2020
The Cancer Breakthroughs 2020 program is one of the most comprehensive cancer collaborative initiative launched to date, seeking to accelerate the potential of combination immunotherapy as the next generation standard of care in cancer patients. This initiative aims to explore a new paradigm in cancer care by initiating randomized Phase II trials in patients at all stages of disease in 20 tumor types in 20,000 patients within the next 36 months. These findings will inform Phase III trials and the aspirational Breakthroughs to develop an effective vaccine-based immunotherapy to combat cancer by 2020. For more information, please visit www.cancerbreakthroughs2020.org and follow Cancer Breakthroughs 2020 on Twitter.
About GPS Cancer™
GPS Cancer™ is a unique, comprehensive test available through NantHealth. GPS Cancer integrates whole genome (DNA) sequencing, whole transcriptome (RNA) sequencing, and quantitative proteomics through mass spectrometry, providing oncologists with a comprehensive molecular profile of a patient’s cancer to inform personalized treatment strategies. GPS Cancer testing is conducted in the CLIA-certified, CAP-accredited laboratory of NantOmics, and is a key enabler for Cancer Breakthroughs 2020, the world’s most comprehensive cancer collaborative initiative seeking to accelerate the potential of combination immunotherapy as the next generation standard of care in cancer patients. For more information, visit www.gpscancer.com and www.cancerbreakthroughs2020.org.